Seqirus USA

Company snapshot

Seqirus (Australia) Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Influenza, Human, Influenza, Influenza Virus. NovaPharmaNews links 9 clinical program(s), 11 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (6), phase 2 (2), approved (1).

• 10 approved product(s) across US/EU regulatory metadata.
• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Seqirus USA. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Seqirus USA.

1. Jun 8, 2026 Clinical update

   V118_18 — Phase 3

2. Jun 8, 2026 Clinical update

   Trivalent influenza vaccine (TIVc) — Phase 2

3. Jun 8, 2026 Clinical update

   Influenza Virus Vaccine — Phase 3

4. Jun 8, 2026 Clinical update

   H5N1 antigen combined with MF59 adjuvant — Phase 2

5. Jun 8, 2026 Clinical update

   CSL Limited Influenza Vaccine — Approved

View all clinical trial activity →

• What is Seqirus USA?

  Seqirus (Australia) Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Influenza, Human, Influenza, Influenza Virus. NovaPharmaNews links 9 clinical program(s), 11 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA,

• Is Seqirus USA publicly traded?

  Seqirus USA appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Seqirus USA develop or market?

  We link 19 drug profile(s) where Seqirus USA is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/seqirus-s-r-l#company-drugs.

• What are the latest developments for Seqirus USA?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Seqirus USA focus on?

  Seqirus USA focuses on Influenza, Human, Influenza, Influenza Virus based on our analysis of their pipeline programs and drug development activities.